Histone Deacetylase Inhibitors and Cancer Therapy
- 1 November 2004
- journal article
- review article
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 16 (sup4) , 64-67
Abstract
Cancer drug development has moved from conventional cytotoxic chemotherapeutics to a more mechanism-based targeted approach towards the common goal of tumour growth arrest. The rapid progress in chromatin research and understanding epigenetic control has supplied a plethora of potential targets for intervention in cancer. Histone deacetylases (HDACs) have been widely implicated in growth and transcriptional control, and inhibition of HDAC activity using small molecules causes apoptosis in tumour cells. Here, we review HDAC inhibitors, together with their current status of clinical development and potential utility in cancer therapy.Keywords
This publication has 11 references indexed in Scilit:
- The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor α-negative breast cancer cells to tamoxifenOncogene, 2003
- Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient miceProceedings of the National Academy of Sciences, 2003
- The cell cycle, chromatin and cancer: mechanism-based therapeutics come of ageDrug Discovery Today, 2003
- The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer CellsCurrent Medicinal Chemistry - Anti-Cancer Agents, 2003
- Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl–positive human acute leukemia cellsBlood, 2003
- Histone deacetylases (HDACs): characterization of the classical HDAC familyBiochemical Journal, 2003
- Calpains Can Do It Alone: Implications for Cancer TherapyCancer Biology & Therapy, 2003
- Valproate and Valproate-Analogues: Potent Tools to Fight Against CancerCurrent Medicinal Chemistry, 2002
- Translating the Histone CodeScience, 2001
- Chronic Oral Administration of CI-994: A Phase I StudyInvestigational New Drugs, 2001